At least 13 studies on 36–248 patients have analyzed the relationship between PD-L1 expression in either tumor cells or immune cells and parameters of urothelial cancer aggressiveness that were unrelated to CPI therapy and found links between high PD-L1 expression and favorable tumor features [7], unfavorable features [8–13] or failed to find relationships to prognostic parameters [14–19]. This evidence concerns the gene CD274 and neoplasm.